Replies to post #234841 on Avid Bioservices Inc (CDMO)

[bidrite]

We have however seen in

A) 2012 with the 2nd ln NSCL interim results that this is not so, the PPS anticipates. This time the market will know PPHM will not lightly announce interim results which will make them the more valuable. The payment from CSM (600K$) is not much but it confirms THEY F..ed. UP our trial and that is what needed to be out there.

B) That if this kind of collaborations/partnerships such as with Memorial Sloan Kettering, AstraZeneca keep coming the marked is going to start looking completely different on PPHM.

C) With Avid II commercialisation of Bavi will be sped up compared to a company that needs to outsource its production to 3rd parties.

D) With the fast track a big part of the BLA is already made and discussed with the FDA. rest assured that Garnick will milk the Fast Trac's possibilities to the last drop.

E) And we haven't either considered an early stop at the look-ins or the granting of a priority Review.

I agree with all of these things, thanks for proving my point that there are NO valid reasons for such a massive increase in dilution. Because we have so many potentially ground breaking news events coming in the short-term, why on earth do we want a shelf so large??